Natixis’s Travere Therapeutics TVTX Stock Holding History

Natixis’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$590K	Buy	+10,387	New	+$461K	﹤0.01%	824
2025 Q4	–	Sell	-3,212	Closed	-$76.8K	–	1310
2025 Q3	$76.8K	Buy	+3,212	New	+$60.4K	﹤0.01%	914
2023 Q4	–	Sell	-163,500	Closed	-$1.46M	–	1174
2023 Q3	$1.46M	Buy	163,500 +28,500	+21%	+$402K	0.01%	450
2023 Q2	$2.07M	Buy	135,000 +94,700	+235%	+$1.72M	0.02%	420
2023 Q1	$906K	Sell	40,300 -874	-2%	-$18.6K	0.01%	541
2022 Q4	$866K	Sell	41,174 -58,826	-59%	-$1.25M	﹤0.01%	658
2022 Q3	$2.56M	Buy	+100,000	New	+$2.58M	0.01%	543
2022 Q2	–	Sell	-65,392	Closed	-$1.69M	–	1366
2022 Q1	$1.69M	Buy	+65,392	New	+$1.74M	0.01%	789

Other funds holding TVTX

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Natixis's TVTX Position: Q2 2026 in Review

Natixis opened a new position in Travere Therapeutics (TVTX) in Q2 2026: 10,387 shares worth $590K. The stake represents ﹤0.01% of the portfolio and ranks #824 among its holdings. This is a return to the name: Natixis previously reported a position in TVTX as recently as Q3 2025.

Natixis first reported a position in TVTX in Q1 2022 and has held it in 8 quarters since. The position peaked at $2.56M in Q3 2022. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

Natixis held 10,387 shares of Travere Therapeutics worth $590K as of Q2 2026.
Travere Therapeutics was a new Natixis position in Q2 2026.
Travere Therapeutics made up ﹤0.01% of Natixis's portfolio in Q2 2026, its #824 holding.
Natixis first reported a position in Travere Therapeutics in Q1 2022 and has held it in 8 quarters since.
Natixis's Travere Therapeutics position peaked at $2.56M in Q3 2022.
321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Natixis's 13F filing for Q2 2026, filed 13 Aug 2026.